Please select an option below to help us tailor your newsletter to best suit your content interests!
Regional One Health and West Cancer Center Partner to Provide Cancer Care at Midtown Location Regional One Health and West Cancer Center and Research Institute have partnered to bring exciting changes to the Midtown cancer center. Effective March 1, 2021, the West Cancer Center Midtown location has transitioned to a hospital outpatient department of Regional… Read more »
Trust your cancer care to our providers at West Cancer Center & Research Institute who authored 119 publications in distinguished medical journals in 2020 alone. We are standing behind our name and respected by leaders in oncology care. Matthew Ballo: VanderWalde NA, Martin MY, Kocak M, Morningstar C, Deal AM, Nyrop KA, Farmer M, Ballo… Read more »
We are with you every step of the way. As a West Cancer Center patient, you and your loved ones have a unique benefit of comprehensive and individualized support throughout your journey here. We have a variety of services specifically dedicated to helping patients identify potential barriers that may prevent them from receiving the best... Read more »
Matching patient populations with a targetable genomic alteration to a specific investigational study is the aim of a new clinical trial through OneR and Genentech. This partnership will facilitate collaborations on various clinical trials, scientific research and real-world data studies that will advance personalized cancer care at community oncology centers like West. “With too many… Read more »
In an effort to further promote social distancing, patients are now able to schedule certain appointments as televisits to speak with their care team from home. Talk to your care team or contact our scheduling department at 901.683.0055 to see if a televisit is right for you!
Choosing the Right Biosimilar for Cancer Care The introduction of biosimilars as anticancer therapies was preceded by a period of supportive care biosimilars. Lee S. Schwartzberg, MD, FACP, describes how he and other clinicians decide which of these agents to use. Well before biosimilar anticancer agents became available, oncologists gained familiarity using biosimilars… Read more »